Panobinostat sensitizes AraC-resistant AML cells to the combination of azacitidine and venetoclax
Jianlei Zhao, Shuangshuang Wu, Deying Wang, Holly Edwards, Jenna Thibodeau, Seongho Kim, Paul M. Stemmer, Guan Wang, Jingji Jin, Süreyya Savaşan, Jeffrey W. Taub, Yubin Ge
Topics & Concepts
PanobinostatAzacitidineVenVenetoclaxCytarabineMyeloid leukemiaMedicineCancer researchCombination therapyAnthracyclineMyeloidLeukemiaHistone deacetylasePharmacologyOncologyInternal medicineChemistryCancerHistoneChronic lymphocytic leukemiaComputer securityBreast cancerBiochemistryComputer scienceGeneDNA methylationGene expressionHistone Deacetylase Inhibitors ResearchAcute Myeloid Leukemia ResearchProtein Degradation and Inhibitors